
    
      Phase I component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2 IV
      over 1 hour, Day 4 Bendamustine escalating cohorts IV over 1 hour, Days 1 and 4 1 Cycle = 28
      days

      Phase II component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2
      IV over 1 hour, Day 4 Bendamustine at MTD IV over 1 hour, Days 1 and 4 Filgrastim (if defined
      in MTD) 5 µg/kg/day SC, Starting day 6 until neutrophil recovery to ANC >1000

      1 Cycle = 28 days; Patients will continue treatment for a total of up to 8 cycles.

      ECOG Performance Status: 0-2

      Hematopoietic:

        -  Absolute neutrophil count (ANC) ≥ 1.2 x K/mm3

        -  Platelets ≥ 75 x K/mm3

      Hepatic:

        -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)

        -  AST ≤ 2.5 x ULN

        -  ALT ≤ 2.5 x ULN

      Renal:

        -  Serum creatinine < 3.0 mg/dL

      Cardiovascular:

        -  LVEF >45% corrected by MUGA scan or echocardiogram.

        -  No unstable angina pectoris or recent myocardial infarction (within 6 months)
    
  